Overview

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Huaota Biopharmaceutical Co., Ltd.